Two AI‑focused startups raised fresh capital to scale computational drug discovery and trial design. Chai Discovery closed a $130 million Series B to expand Chai‑2, its de‑novo antibody generative platform that the company says achieved double‑digit experimental success rates across diverse targets. The funding will accelerate product development and commercialization of a computer‑aided design suite for antibodies. Separately, Valinor secured $13 million in seed financing to develop multi‑omics machine‑learning models aimed at improving clinical trial design and patient responder identification. Both rounds signal investor confidence in AI‑first approaches that shorten design‑to‑experiment cycles and aim to reduce preclinical and clinical attrition.